<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-01-18</title>
    <style>
        :root {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-01-18</p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">38</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">3</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-01-18 22:11</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                ## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºç›‘ç®¡æ”¿ç­–è°ƒæ•´ä¸é‡ç£…è¯ç‰©å¸‚åœºè¡¨ç°ã€‚FDAæ­£è°ƒæ•´ä¸€æœŸä¸´åºŠè¯•éªŒè§„å®šä»¥åº”å¯¹ä¸­å›½ç”Ÿç‰©æŠ€æœ¯å´›èµ·ï¼ŒåŒæ—¶åŠ é€Ÿå®¡æ‰¹é¡¹ç›®é¢ä¸´ä¼ä¸šæ‹…å¿§ï¼›GLP-1è¯ç‰©å¸‚åœºæŒç»­ç«çƒ­ï¼Œè¯ºå’Œè¯ºå¾·å£æœç‰ˆWegovyä¸Šå¸‚é¦–å‘¨å¤„æ–¹é‡è¶…3000ä»½ï¼Œæ˜¾ç¤ºå‡è‚¥è¯é¢†åŸŸç«äº‰ç™½çƒ­åŒ–ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**1. Makary talks FDA's plans to combat China's biotech growth** â­â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - FDAå±€é•¿æ˜ç¡®è¡¨æ€å°†è°ƒæ•´ä¸€æœŸè¯•éªŒè§„å®šä»¥åº”å¯¹ä¸­å›½ç”Ÿç‰©æŠ€æœ¯å´›èµ·ï¼Œåæ˜ å…¨çƒç”Ÿç‰©åŒ»è¯ç«äº‰æ ¼å±€å˜åŒ–

**3. Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading** â­â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - è¯ºå’Œè¯ºå¾·å£æœGLP-1è¯ç‰©ä¸Šå¸‚é¦–å‘¨å¤„æ–¹é‡è¶…3000ä»½ï¼Œæ˜¾ç¤ºå‡è‚¥è¯å¸‚åœºè¿›å…¥æ–°å‰‚å‹ç«äº‰é˜¶æ®µ

**21. AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study** â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - è‰¾ä¼¯ç»´ä¸Genmabçš„æ·‹å·´ç˜¤è¯ç‰©ä¸‰æœŸè¯•éªŒæœªè¾¾åˆ°æ€»ç”Ÿå­˜æœŸç»ˆç‚¹ï¼Œå½±å“è¯¥äº§å“å¸‚åœºå‰æ™¯

**8. STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - å¤§å‹è¯ä¼å› æ³•å¾‹é£é™©å¯¹FDAåŠ é€Ÿå®¡æ‰¹é¡¹ç›®æŒè°¨æ…æ€åº¦ï¼Œåæ˜ ç›‘ç®¡æ”¿ç­–æ‰§è¡Œé¢ä¸´æŒ‘æˆ˜

**30. #JPM26: Sandoz CEO on Ozempic generic launch plans for 2026** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - å±±å¾·å£«CEOåœ¨JPMå¤§ä¼šä¸Šé€éœ²2026å¹´æ¨å‡ºOzempicä»¿åˆ¶è¯è®¡åˆ’ï¼Œå°†å†²å‡»GLP-1è¯ç‰©å¸‚åœºæ ¼å±€

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): Exelixiså‡­å€Ÿå•ä¸€è¯ç‰©Cabometyxç„å‡†ç¾å›½å®ä½“ç˜¤å‰äº”åœ°ä½ï¼›ImmunityBioçš„ç°è´§å‹ç»†èƒç–—æ³•åœ¨ç½•è§è¡€ç™Œæ—©æœŸè¯•éªŒä¸­æ˜¾ç¤ºæ½œåŠ›ï¼›Agomabä¸SpyGlassæäº¤IPOç”³è¯·ï¼Œæ˜¾ç¤ºæŠ•èµ„è€…å¯¹ç”Ÿç‰©æŠ€æœ¯é¢†åŸŸçƒ­æƒ…å›å‡
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): è‰¾ä¼¯ç»´/Genmabçš„Epkinlyåœ¨å¼¥æ¼«æ€§å¤§Bç»†èƒæ·‹å·´ç˜¤ä¸‰æœŸè¯•éªŒä¸­æœªæ”¹å–„æ€»ç”Ÿå­˜æœŸï¼›FDAåŠ é€Ÿå®¡æ‰¹é¡¹ç›®ä¸­éƒ¨åˆ†ç™Œç—‡è¯ç‰©å·²éªŒè¯ä¸´åºŠè·ç›Šï¼›EMAåœ¨2025å¹´æ¨è38ç§æ–°è¯ï¼Œæ¯”FDAå°‘15ç§

### ğŸ”® æ˜æ—¥å…³æ³¨

éœ€å…³æ³¨FDAå¯¹ä¸€æœŸè¯•éªŒè§„å®šçš„å…·ä½“è°ƒæ•´æ–¹æ¡ˆåŠå…¶å¯¹ä¸­ç¾ç”Ÿç‰©æŠ€æœ¯ç«äº‰çš„å½±å“ï¼›å±±å¾·å£«GLP-1ä»¿åˆ¶è¯å…·ä½“ä¸Šå¸‚æ—¶é—´è¡¨åŠå®šä»·ç­–ç•¥ï¼›æœ€é«˜æ³•é™¢å°†å®¡ç†Hikmaä¸Amarinçš„'ç˜¦èº«æ ‡ç­¾'è¯‰è®¼æ¡ˆï¼Œç»“æœå¯èƒ½å½±å“ä»¿åˆ¶è¯æ ‡ç­¾æ³•è§„

            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">12 æ¡</span>
                </div>

                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Makary talks FDA&#39;s plans to combat China&#39;s biotech growth
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 19:51</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As China sees increased biotech investments, licensing deals and faster early-phase clinical trial starts, FDA Commissioner Marty Makary said his agency is reworking Phase 1 trial regulations to speed that entry process and tweaking user ...</p>
                    
                    <a href="https://endpoints.news/makary-talks-fdas-plans-to-combat-chinas-biotech-growth/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-16 16:24</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">More than 3,000 prescriptions were written for Novo&amp;rsquo;s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading scandal and Sanofi is reportedly circling an eye drug biotech.</p>
                    
                    <a href="https://www.biopharmadive.com/news/wegovy-pill-sales-emergent-sanofi-ocular-jazz-novo/809709/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 22:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening. The drug developers hope to build on the strong start set by Aktis Oncologyâ€™s $318 million Nasdaq listing last ...</p>
                    
                    <a href="https://endpoints.news/agomab-and-spyglass-file-for-ipos-as-investor-enthusiasm-builds-after-jpm/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugmakers without MFN pacts are bracing to make one
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 20:48</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">All but 17 drugmakers avoided a direct demand from President Donald Trump last year to lower their prices significantly. But that likely wonâ€™t last. There was a subtle unease among executives of some of the ...</p>
                    
                    <a href="https://endpoints.news/drugmakers-without-mfn-pacts-are-bracing-to-make-one/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 12:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The European Medicines Agency recommended 104 medicines for approval in 2025, the second-highest number in the past 15 years, according to a report the agency published Thursday. Of the positive recommendations ...</p>
                    
                    <a href="https://endpoints.news/european-regulators-recommended-38-novel-drugs-in-2025-15-fewer-than-the-fda/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie, Genmab say Epkinly didn&#39;t prolong overall survival in lymphoma study
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 21:01</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AbbVie and Genmabâ€™s cancer drug Epkinly failed to improve overall survival in a late-stage study for diffuse large B cell lymphoma. The Phase 3 trial enrolled patients who had received at least one prior therapy ...</p>
                    
                    <a href="https://endpoints.news/abbvie-genmab-say-epkinly-didnt-prolong-overall-survival-in-lymphoma-study/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ImmunityBio&#39;s cell therapy posts encouraging early data in rare blood cancer
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 16:05</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">ImmunityBioâ€™s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma. The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with WaldenstrÃ¶m non ...</p>
                    
                    <a href="https://endpoints.news/immunitybio-cell-therapy-posts-encouraging-early-data-in-rare-blood-cancer/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        On biotechâ€™s biggest stage, renewed excitement gets a stress test
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-16 11:43</span>
                        
                    </div>
                    
                    <p class="news-summary">A surge in deals and financings had the industry abuzz heading into this year&amp;rsquo;s J.P. Morgan Healthcare Conference. But some aren&amp;rsquo;t sure if the rebound is here to stay.</p>
                    
                    <a href="https://www.biopharmadive.com/news/jpm26-biotech-startups-deals-venture-ipo-fda-china/809809/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM recap; Mirador raises $250M; Genentechâ€™s PBM shift; and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-17 11:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We wonâ€™t be sending newsletters on Monday, but weâ€™ll be back in your inbox on Tuesday. The Endpoints News ...</p>
                    
                    <a href="https://endpoints.news/jpm-recap-mirador-raises-250m-genentechs-pbm-shift-and-more/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Supreme Court will hear Hikmaâ€™s â€˜skinny labelâ€™ fight against Amarin
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 20:06</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/supreme-court-will-hear-hikmas-skinny-label-fight-against-amarin/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #JPM26: Sandoz CEO on Ozempic generic launch plans for 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 14:42</span>
                        
                    </div>
                    
                    <p class="news-summary">SAN FRANCISCO â€” Throughout his 53 meetings at this year&#39;s JPMorgan Healthcare Conference, Richard Saynor mulled a charitable idea about the topic on everyone&#39;s minds. &#34;We&#39;re going to put a cup in the middle of ...</p>
                    
                    <a href="https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">â†’ These days, itâ€™s just not Peer Review without Novo Nordisk: Anja Leth Zimmer said on LinkedIn that she had been promoted to chief AI officer at the Danish pharma, which ...</p>
                    
                    <a href="https://endpoints.news/novo-nordisk-biomarin-make-ai-moves-bristol-myers-welcomes-neurology-exec-from-eisai/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">18 æ¡</span>
                </div>

                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Verified Clinical Benefit | Cancer Accelerated Approvals
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 15:17</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Safety Oversight Board
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 21:17</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The DSB is composed of representatives from two FDA Centers and eight other federal government agencies, the Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Department of Defense.</p>
                    
                    <a href="http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-safety-oversight-board" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patient Listening Session Summaries
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 21:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.</p>
                    
                    <a href="http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Resources for Biomarker Requestors
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 21:11</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Information and resources for requestors about FDAâ€™s Biomarker Qualification Program</p>
                    
                    <a href="http://www.fda.gov/drugs/biomarker-qualification-program/resources-biomarker-requestors" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tips for Section 804 Importation Program Proposals (SIPs)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 18:39</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDAâ€™s tips for section 804 state importation program (SIP) proposals provide information to assist states and tribes develop their proposals.</p>
                    
                    <a href="http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/tips-section-804-importation-program-proposals-sips" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Section 804 Importation Program Policies and Authorizations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:17</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA has issued policies and taken actions to implement section 804 of the Federal Food, Drug and Cosmetic Act, which allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.</p>
                    
                    <a href="http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-policies-and-authorizations" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Section 804 Importation Program (SIP) Proposals and FDAâ€™s Review Process
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Section 804 of the Federal Food, Drug and Cosmetic Act allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs without imposing additional risk to public health and safety.</p>
                    
                    <a href="http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-sip-proposals-and-fdas-review-process" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Importation Program under Section 804 of the FD&amp;C Act
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA has developed a pathway under section 804 of the Federal Food, Drug, and Cosmetic Act (FD&amp;amp;C Act) that allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.</p>
                    
                    <a href="http://www.fda.gov/drugs/human-drug-imports/importation-program-under-section-804-fdc-act" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA Authorizes Floridaâ€™s Drug Importation Program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:04</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA authorized Floridaâ€™s Agency for Health Care Administrationâ€™s Section 804 Importation Program (SIP) in accordance with section 804 of the Federal Food, Drug, and Cosmetic Act (FD&amp;amp;C Act) and the FDAâ€™s implementing regulations.</p>
                    
                    <a href="http://www.fda.gov/news-events/press-announcements/fda-authorizes-floridas-drug-importation-program" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        State Importation Program Enhancements
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 16:54</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA is committed to continuing to work with states and Indian tribes that seek to develop an importation proposal under section 804 of the Federal Food, Drug and Cosmetic Act.</p>
                    
                    <a href="http://www.fda.gov/about-fda/reports/state-importation-program-enhancements" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 15:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        My Dog Has Cancer: What Do I Need to Know?
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 13:44</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Just as FDA reviews drugs for humans for safety and effectiveness before they can go on the market, the agency does the same for treatments for animals. Learn how FDA brings new oncology treatments to market and questions to ask your vet about your dog&#39;s cancer diagnosis.</p>
                    
                    <a href="http://www.fda.gov/consumers/consumer-updates/my-dog-has-cancer-what-do-i-need-know" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted  under PREA from 2012 â€“ present
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 18:40</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The following are the medical, statistical, and clinical pharmacology reviews of pediatric studies conducted in response to a Written Request issued under the BPCA and pediatric assessments conducted under PREA.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 23:19</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Section 804 Importation Program Quality Assurance Tool
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:14</span>
                        
                    </div>
                    
                    <p class="news-summary">This quality assurance (QA) tool is designed to assist section 804 importation program (SIP) sponsors prepare proposals that fully comply with the requirements under the final rule.</p>
                    
                    <a href="http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-quality-assurance-tool" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Human Drug Imports
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 16:53</span>
                        
                    </div>
                    
                    <p class="news-summary">Human drug import information including PLAIR, safe importation action plan, and personal importation policy.</p>
                    
                    <a href="http://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-imports" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Recently Issued Guidance Documents
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 15:59</span>
                        
                    </div>
                    
                    <p class="news-summary">This page lists Recently Issued CBER and Cross-Center Guidance Documents.</p>
                    
                    <a href="http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 14:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: FDA delays reviews for two drugs in new voucher program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 14:36</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 14:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Some major drugmakers are hesitating to participate in the Trump administration&#39;s speedier review program for new medicines over possible legal risks</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        &lt;a href=&#34;https://www.fiercepharma.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us&#34; hreflang=&#34;en&#34;&gt;Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO&lt;/a&gt;
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:16</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        &lt;a href=&#34;https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next&#34; hreflang=&#34;en&#34;&gt;After AbbVie and Genmab&#39;s ph. 3 survival miss for Epkinly in DLBCL, what&#39;s next?&lt;/a&gt;
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 15:29</span>
                        
                    </div>
                    
                    <p class="news-summary">Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        &lt;a href=&#34;https://www.fiercepharma.com/pharma/jpm26-fujifilm-ceo-touts-biologics-capacity-edge-manufacturing-unit-keeps-expansions-coming&#34; hreflang=&#34;en&#34;&gt;JPM26: Fujifilm CEO touts biologics capacity edge amid expansion tear&lt;/a&gt;
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:52</span>
                        
                    </div>
                    
                    <p class="news-summary">With Fujifilm Biotechnologies now among the top echelon of CDMOs by biologics capacity, Fujifilmâ€™s group CEO reflected on the unitâ€™s unique facility design philosophy and how itâ€™s eschewing big M&amp;amp;A plays to expand in-house.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jpm26-fujifilm-ceo-touts-biologics-capacity-edge-manufacturing-unit-keeps-expansions-coming" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        &lt;a href=&#34;https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit&#34; hreflang=&#34;en&#34;&gt;AbbVieâ€™s Skyrizi takes full-year TV ad spending crown yet again, with J&amp;amp;Jâ€™s Tremfya in hot pursuit&lt;/a&gt;
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:49</span>
                        
                    </div>
                    
                    <p class="news-summary">For the fourth year runningâ€”and the third in a row for Skyrizi specificallyâ€”an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 21:03</span>
                        
                    </div>
                    
                    <p class="news-summary">The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 17:00</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-01-18 22:11</p>
        </footer>
    </div>
</body>
</html>